Showing 7181-7190 of 8826 results for "".
- New Eczema Relief Balm Available From Avènehttps://practicaldermatology.com/news/new-eczema-relief-balm-available-avene/2468441/French skincare brand Avène introduced XeraCalm Eczema Calming Relief Balm and Cicalfate+ Intensive Skin Restoration Serum, two new innovations that feature the company’s mineral-rich Thermal Spring Water. “These breakthrough formulations are at the heart of how Eau Thermale Avène cares fo
- Botox Approved for Platysma Bandshttps://practicaldermatology.com/news/botox-approved-platysma-bands/2468436/The US Food and Drug Administration (FDA) has approved BOTOX® Cosmetic for temporary improvement in the appearance of moderate-to-severe vertical bands connecting the jaw and neck (platysma bands) in adults, Allergan Aesthetics, an AbbVie company, announced. According to a press release, B
- ZORYVE Foam Approved in Canada for Seborrheic Dermatitishttps://practicaldermatology.com/news/zoryve-foam-approved-canada-seborrheic-dermatitis/2468434/Health Canada has approved ZORYVE (roflumilast) foam 0.3% for treating seborrheic dermatitis in individuals aged nine and older, according to a press release from Arcutis. The approval makes ZORYVE the first new topical treatment for the condition approved in Canada in over 20 years. The a
- Dupilumab Shows Superior Drug Survival in Pediatric Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/dupilumab-shows-superior-drug-survival-pediatric-atopic-dermatitis-treatment/2468431/New research shows dupilumab was superior drug survival compared to methotrexate (MTX) and cyclosporine A (CsA) in pediatric patients with atopic dermatitis (AD), and with lower rates of treatment discontinuation. The study, published in JAMA Dermatology, conducted across five ter
- European Decentralized Regulatory Procedure Completed for Efinaconazolehttps://practicaldermatology.com/news/european-decentralized-regulatory-procedure-completed-efinaconazole/2468407/Almirall, S.A. announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole, a triazole antifungal compound indicated for the treatment of onychomycosis, under the trade name of Jublia®. The low binding affinity of efinaconazole topical to kerat
- Study Analyzes Metabolites and ADhttps://practicaldermatology.com/news/study-analyzes-metabolites-and-ad/2468384/Bidirectional two-sample Mendelian randomization (MR) analyses in a study published in Scientific Reports indicated that 22 metabolites and one inflammatory protein (S100A12) were significantly associated with atopic dermatitis (AD) pathogenesis. “The levels of amino acid metaboli
- FDA Approves Up To 3 Tubes of Ameluz Topical Gel, 10% In 1 Treatmenthttps://practicaldermatology.com/news/fda-approves-3-tubes-ameluz-topical-gel-10-1-treatment/2468368/The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to increase the maximally approved dosage from one to three tubes of Biofrontera Inc.’s Ameluz® per treatment, the company announced. Biofrontera Inc. said in a press release that the approval
- Avene Partners With Dermatology Influencer at Ulta Beautyhttps://practicaldermatology.com/news/avene-partners-dermatology-influencer-ulta-beauty/2468359/Avene has announced a new partnership to bridge the gap between dermatological education and daily skincare, according to a news release. The French skincare brand is partnering with renowned boar
- TRuE AD3: Ruxolitinib Safety and Efficacy Confirmed in Children with Atopic Dermatitishttps://practicaldermatology.com/news/52-week-study-validates-ruxolitinibs-safety-and-efficacy-in-children-with-ad/2468353/Ruxolitinib cream (RUX) demonstrated long-term safety and efficacy in children aged 2 to 11 with mild-to-moderate atopic dermatitis (AD), with over 60% of patients achieving clear or nearly clear skin, according to updated data presented recently at the 2024 European Academy of Dermatology and Ve
- Triple-Combination Acne Treatment Shows Equal Efficacy Across Sexeshttps://practicaldermatology.com/news/triple-combination-acne-treatment-shows-equal-efficacy-across-sexes/2468352/A post hoc analysis of two phase 3 studies showed clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) had s